AVN is up 185 % in 4 months. -- Stock Picks

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 02:48:59 09/01/00 Fri
Author: AVN is up 185 % in 4 months.
Subject: AVN is up 185 % in 4 months.

AVN is up 185 % in 4 months.
SEPT. 1st is HERE!
AVN has soared 185% since the May 1st.
It seems as though shareholders are scrambling for shares before the opening of Xenerex, a newly formed division of AVN. Xenerex will
open with the distinct goal of providing fully human monoclonal antibodies to Pharmacutical and Biotech companies worldwide.
AVN recently formed Xenerex to compete with high flyers such as ABGX & MEDX. Both ABGX and MEDX soared earlier this year
based on technology similar to AVN's. ABGX went to 400+ in the bull market (before announcing 2 splits) and MEDX soared to 200+.
AVN says Xenerex will open for business Sept. 1 and they are already in discussions with possible partners. In a recent interview Gregory
Hansen, Xenerex President is touting the Xenerex mouse as having great advantages over the competition.

"Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human antibodies faster and cheaper than its
competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody Technology plc, Hansen said. "

Bioworld Online,
Aug 21, 2000

Also bear in mind that AVN will post profits next quarter due to the FDA approval of the first
Over-The-Counter Herpes Cream.

http://biz.yahoo.com/p/a/avn.html

http://www.avanir.com/

[ Next Thread | Previous Thread | Next Message | Previous Message ]